Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The importance of the trans-enamine intermediate as a β-lactamase inhibition strategy probed in inhibitor-resistant SHV β-lactamase variants.

Ke W, Rodkey EA, Sampson JM, Skalweit MJ, Sheri A, Pagadala SR, Nottingham MD, Buynak JD, Bonomo RA, van den Akker F.

ChemMedChem. 2012 Jun;7(6):1002-8. doi: 10.1002/cmdc.201200006. Epub 2012 Mar 21.

2.

Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition.

Rodkey EA, Winkler ML, Bethel CR, Pagadala SR, Buynak JD, Bonomo RA, van den Akker F.

PLoS One. 2014 Jan 16;9(1):e85892. doi: 10.1371/journal.pone.0085892. eCollection 2014.

3.

Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.

Totir MA, Padayatti PS, Helfand MS, Carey MP, Bonomo RA, Carey PR, van den Akker F.

Biochemistry. 2006 Oct 3;45(39):11895-904.

4.

Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.

Helfand MS, Taracila MA, Totir MA, Bonomo RA, Buynak JD, van den Akker F, Carey PR.

Biochemistry. 2007 Jul 24;46(29):8689-99. Epub 2007 Jun 27.

PMID:
17595114
5.

Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.

Padayatti PS, Sheri A, Totir MA, Helfand MS, Carey MP, Anderson VE, Carey PR, Bethel CR, Bonomo RA, Buynak JD, van den Akker F.

J Am Chem Soc. 2006 Oct 11;128(40):13235-42.

6.

High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.

Padayatti PS, Helfand MS, Totir MA, Carey MP, Carey PR, Bonomo RA, van den Akker F.

J Biol Chem. 2005 Oct 14;280(41):34900-7. Epub 2005 Jul 29.

7.

Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors.

Kalp M, Bethel CR, Bonomo RA, Carey PR.

Biochemistry. 2009 Oct 20;48(41):9912-20. doi: 10.1021/bi9012098.

8.

Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.

Padayatti PS, Helfand MS, Totir MA, Carey MP, Hujer AM, Carey PR, Bonomo RA, van den Akker F.

Biochemistry. 2004 Feb 3;43(4):843-8.

PMID:
14744126
9.

Avibactam and inhibitor-resistant SHV β-lactamases.

Winkler ML, Papp-Wallace KM, Taracila MA, Bonomo RA.

Antimicrob Agents Chemother. 2015 Jul;59(7):3700-9. doi: 10.1128/AAC.04405-14. Epub 2015 Feb 17.

10.
11.

Insight into the effect of inhibitor resistant S130G mutant on physico-chemical properties of SHV type beta-lactamase: a molecular dynamics study.

Baig MH, Sudhakar DR, Kalaiarasan P, Subbarao N, Wadhawa G, Lohani M, Khan MK, Khan AU.

PLoS One. 2014 Dec 5;9(12):e112456. doi: 10.1371/journal.pone.0112456. eCollection 2014.

12.

Crystal structure of a preacylation complex of the β-lactamase inhibitor sulbactam bound to a sulfenamide bond-containing thiol-β-lactamase.

Rodkey EA, Drawz SM, Sampson JM, Bethel CR, Bonomo RA, van den Akker F.

J Am Chem Soc. 2012 Oct 10;134(40):16798-804. doi: 10.1021/ja3073676. Epub 2012 Sep 26.

13.

Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.

Ke W, Sampson JM, Ori C, Prati F, Drawz SM, Bethel CR, Bonomo RA, van den Akker F.

Antimicrob Agents Chemother. 2011 Jan;55(1):174-83. doi: 10.1128/AAC.00930-10. Epub 2010 Nov 1.

14.

Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M, Anderson VE, Fritsche TR, Jones RN, Pagadala SR, van den Akker F, Buynak JD, Bonomo RA.

J Biol Chem. 2009 Jan 9;284(2):945-53. doi: 10.1074/jbc.M806833200. Epub 2008 Oct 27.

15.

Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA.

Antimicrob Agents Chemother. 2015 Jul;59(7):3710-7. doi: 10.1128/AAC.04406-14. Epub 2015 Feb 9.

16.

Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.

Nukaga M, Bethel CR, Thomson JM, Hujer AM, Distler A, Anderson VE, Knox JR, Bonomo RA.

J Am Chem Soc. 2008 Sep 24;130(38):12656-62. doi: 10.1021/ja7111146. Epub 2008 Aug 30.

17.

Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.

Sulton D, Pagan-Rodriguez D, Zhou X, Liu Y, Hujer AM, Bethel CR, Helfand MS, Thomson JM, Anderson VE, Buynak JD, Ng LM, Bonomo RA.

J Biol Chem. 2005 Oct 21;280(42):35528-36. Epub 2005 Jun 29.

18.

Homology modeling and virtual screening of inhibitors against TEM- and SHV-type-resistant mutants: A multilayer filtering approach.

Baig MH, Balaramnavar VM, Wadhwa G, Khan AU.

Biotechnol Appl Biochem. 2015 Sep-Oct;62(5):669-80. doi: 10.1002/bab.1370. Epub 2015 Jul 2.

PMID:
25779642
19.

Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.

Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR.

Biochemistry. 2007 Aug 7;46(31):8980-7. Epub 2007 Jul 13.

20.

Computational redesign of the SHV-1 beta-lactamase/beta-lactamase inhibitor protein interface.

Reynolds KA, Hanes MS, Thomson JM, Antczak AJ, Berger JM, Bonomo RA, Kirsch JF, Handel TM.

J Mol Biol. 2008 Oct 24;382(5):1265-75. doi: 10.1016/j.jmb.2008.05.051. Epub 2008 May 29.

Supplemental Content

Support Center